### 1. Introduction

Acute lymphoblastic leukemia (ALL) and CD33

- The 5-year survival rate for children with ALL is now greater than 90% (Siegel et al., 2013) but children with certain high-risk subtypes experience a far less favorable prognosis.

- CD33 is expressed on the surface of B-ALL blasts and is associated with aggressive disease subtypes such as Ph+ ALL and is a target in directing novel therapeutic strategies (Lydon et al., 2006; Angelova et al., 2015).

- CD33 serves to facilitate immune evasion of leukemia cells and is therefore a target for therapeutic intervention.

- In particular, CD33 has been demonstrated to be a target for antibody-drug conjugates (ADCs) in preclinical models of pediatric B-ALL.

- The objective response categories are as described by Houghton et al., 2007.

- The Kaplan-Meier method compared event-free survival (EFS) between treated and control groups.

- Events were defined when the proportion of human CD45+ cells (%huCD45+) in the peripheral blood time after treatment initiation relative to the %huCD45+ at Day 0.

- The 5-year survival rate for children with ALL is now greater than 90% (Siegel et al., 2013) but children with certain high-risk subtypes experience a far less favorable prognosis.

- CD33 is expressed on the surface of B-ALL blasts and is associated with aggressive disease subtypes such as Ph+ ALL and is a target in directing novel therapeutic strategies (Lydon et al., 2006; Angelova et al., 2015).

- CD33 serves to facilitate immune evasion of leukemia cells and is therefore a target for therapeutic intervention.

- In particular, CD33 has been demonstrated to be a target for antibody-drug conjugates (ADCs) in preclinical models of pediatric B-ALL.

- The objective response categories are as described by Houghton et al., 2007.

- The Kaplan-Meier method compared event-free survival (EFS) between treated and control groups.

- Events were defined when the proportion of human CD45+ cells (%huCD45+) in the peripheral blood time after treatment initiation relative to the %huCD45+ at Day 0.

- The 5-year survival rate for children with ALL is now greater than 90% (Siegel et al., 2013) but children with certain high-risk subtypes experience a far less favorable prognosis.

- CD33 is expressed on the surface of B-ALL blasts and is associated with aggressive disease subtypes such as Ph+ ALL and is a target in directing novel therapeutic strategies (Lydon et al., 2006; Angelova et al., 2015).

- CD33 serves to facilitate immune evasion of leukemia cells and is therefore a target for therapeutic intervention.

- In particular, CD33 has been demonstrated to be a target for antibody-drug conjugates (ADCs) in preclinical models of pediatric B-ALL.

- The objective response categories are as described by Houghton et al., 2007.

- The Kaplan-Meier method compared event-free survival (EFS) between treated and control groups.

- Events were defined when the proportion of human CD45+ cells (%huCD45+) in the peripheral blood time after treatment initiation relative to the %huCD45+ at Day 0.

- The 5-year survival rate for children with ALL is now greater than 90% (Siegel et al., 2013) but children with certain high-risk subtypes experience a far less favorable prognosis.

- CD33 is expressed on the surface of B-ALL blasts and is associated with aggressive disease subtypes such as Ph+ ALL and is a target in directing novel therapeutic strategies (Lydon et al., 2006; Angelova et al., 2015).

- CD33 serves to facilitate immune evasion of leukemia cells and is therefore a target for therapeutic intervention.

- In particular, CD33 has been demonstrated to be a target for antibody-drug conjugates (ADCs) in preclinical models of pediatric B-ALL.

- The objective response categories are as described by Houghton et al., 2007.

- The Kaplan-Meier method compared event-free survival (EFS) between treated and control groups.

- Events were defined when the proportion of human CD45+ cells (%huCD45+) in the peripheral blood time after treatment initiation relative to the %huCD45+ at Day 0.

- The 5-year survival rate for children with ALL is now greater than 90% (Siegel et al., 2013) but children with certain high-risk subtypes experience a far less favorable prognosis.

- CD33 is expressed on the surface of B-ALL blasts and is associated with aggressive disease subtypes such as Ph+ ALL and is a target in directing novel therapeutic strategies (Lydon et al., 2006; Angelova et al., 2015).

- CD33 serves to facilitate immune evasion of leukemia cells and is therefore a target for therapeutic intervention.

- In particular, CD33 has been demonstrated to be a target for antibody-drug conjugates (ADCs) in preclinical models of pediatric B-ALL.

- The objective response categories are as described by Houghton et al., 2007.

- The Kaplan-Meier method compared event-free survival (EFS) between treated and control groups.

- Events were defined when the proportion of human CD45+ cells (%huCD45+) in the peripheral blood time after treatment initiation relative to the %huCD45+ at Day 0.

- The 5-year survival rate for children with ALL is now greater than 90% (Siegel et al., 2013) but children with certain high-risk subtypes experience a far less favorable prognosis.

- CD33 is expressed on the surface of B-ALL blasts and is associated with aggressive disease subtypes such as Ph+ ALL and is a target in directing novel therapeutic strategies (Lydon et al., 2006; Angelova et al., 2015).

- CD33 serves to facilitate immune evasion of leukemia cells and is therefore a target for therapeutic intervention.

- In particular, CD33 has been demonstrated to be a target for antibody-drug conjugates (ADCs) in preclinical models of pediatric B-ALL.

- The objective response categories are as described by Houghton et al., 2007.

- The Kaplan-Meier method compared event-free survival (EFS) between treated and control groups.

- Events were defined when the proportion of human CD45+ cells (%huCD45+) in the peripheral blood time after treatment initiation relative to the %huCD45+ at Day 0.

- The 5-year survival rate for children with ALL is now greater than 90% (Siegel et al., 2013) but children with certain high-risk subtypes experience a far less favorable prognosis.

- CD33 is expressed on the surface of B-ALL blasts and is associated with aggressive disease subtypes such as Ph+ ALL and is a target in directing novel therapeutic strategies (Lydon et al., 2006; Angelova et al., 2015).

- CD33 serves to facilitate immune evasion of leukemia cells and is therefore a target for therapeutic intervention.

- In particular, CD33 has been demonstrated to be a target for antibody-drug conjugates (ADCs) in preclinical models of pediatric B-ALL.

- The objective response categories are as described by Houghton et al., 2007.

- The Kaplan-Meier method compared event-free survival (EFS) between treated and control groups.

- Events were defined when the proportion of human CD45+ cells (%huCD45+) in the peripheral blood time after treatment initiation relative to the %huCD45+ at Day 0.